Novo Nordisk A/S purchases B shares worth DKK 1.1 billion from Novo A/S as part of the ongoing share repurchase programme (7 August 2009)
| Read the full announcement in PDF format |
Novo Nordisk A/S has today entered into an agreement to purchase 3,570,000 B shares (nominal DKK 1) from Novo A/S on 10 August 2009 as part of the ongoing DKK 19.0 billion share repurchase programme for 2006-2009. The transaction price is set to DKK 311.125 per share and has been calculated as the average market price from 6 August to 7 August in the open trading window following the announcement of Novo Nordisk's financial results for the first six months of 2009.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.
Novo A/S, the holding company in the Novo Group, was established prior to the demerger of Novo Nordisk in 2000. Novo A/S is a private limited liability company, fully owned by the Novo Nordisk Foundation. Besides being the majority shareholder in Novozymes A/S and Novo Nordisk A/S, Novo A/S provides venture capital to development stage companies with pioneering scientific ideas within life science, and assists the Novo Group companies in implementing and evaluating the commitments set out in the 'Charter for Companies in the Novo Group'. For more information, visit novo.dk.
Further information on Novo Nordisk A/S please contact:
Media: | Investors: |
Outside North America: | Outside North America: |
Elin K Hansen | Mads Veggerby Lausten |
Tel: (+45) 4442 3450 | Tel: (+45) 4443 7919 |
Kasper Roseeuw Poulsen | |
Tel: (+45) 4442 4471 | |
In North America: | In North America: |
Sean Clements | Hans Rommer |
Tel: (+1) 609 514 8316 | Tel: (+1) 609 919 7937 |
Further information on Novo A/S please contact:
Media:
Henrik Gürtler, CEO
Tel: (+45) 4442 2189
Thorkil Kastberg Christensen, CFO
Tel: (+45) 4442 3197
Company Announcement no 48 / 2009
More about RSS feeds
